Omjara tablets 100mg, manufactured by GlaxoSmithKline, contains Momelotinib hydrochloride (YJ code: 4291083F1022, standard: 100mg 1 tablet). This kinase inhibitor targets JAK1, JAK2, and ACVR1, and is indicated for intermediate or high-risk myelofibrosis in adults with anemia. Its mechanism of action addresses splenomegaly and symptoms while also improving anemia by reducing hepcidin levels.
Omjara tablets 100mg
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →
